Psilocybin is a psychedelic tryptamine that has shown promise in recent clinical trials for the treatment of depression and substance use disorders. This open-label study of the pharmacokinetics of psilocybin was performed to describe the pharmacokinetics and safety profile of psilocybin in sequential, escalating oral doses of 0.3, 0.45, and 0.6 mg/kg in 12 healthy adults.
Brown, R. T., et al. (2017). “Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.” Clinical Pharmacokinetics 56(12): 1543-1554.